Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 738 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers April 25, 2019 Strengthening EU Support for Rare Cancers under the 2028–2034 Multiannual Financial... November 17, 2025 Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... March 14, 2022 How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives December 14, 2023 Load more HOT NEWS Mom Says Family Was Kicked Out Of Movie Theater Because Her... Hiding in plain sight: How we can use immune cells to... What Cancer Survivors Should Know About Survivorship Research: Expert Perspectives Teacher Visits Student Battling Cancer At Home To Help With His...
